TD Cowen lowered the firm’s price target on Ascendis Pharma (ASND) to $153 from $160 and keeps a Buy rating on the shares. The firm said its target moved lower folowing the Q3 Skytrofa revenue miss and lowered guidance.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND: